JP2018503600A5 - - Google Patents

Download PDF

Info

Publication number
JP2018503600A5
JP2018503600A5 JP2017526592A JP2017526592A JP2018503600A5 JP 2018503600 A5 JP2018503600 A5 JP 2018503600A5 JP 2017526592 A JP2017526592 A JP 2017526592A JP 2017526592 A JP2017526592 A JP 2017526592A JP 2018503600 A5 JP2018503600 A5 JP 2018503600A5
Authority
JP
Japan
Prior art keywords
antibody
pharmaceutical composition
amino acid
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017526592A
Other languages
English (en)
Japanese (ja)
Other versions
JP6951973B2 (ja
JP2018503600A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/060287 external-priority patent/WO2016077526A1/en
Publication of JP2018503600A publication Critical patent/JP2018503600A/ja
Publication of JP2018503600A5 publication Critical patent/JP2018503600A5/ja
Priority to JP2021066180A priority Critical patent/JP2021118699A/ja
Application granted granted Critical
Publication of JP6951973B2 publication Critical patent/JP6951973B2/ja
Priority to JP2023034165A priority patent/JP2023063357A/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017526592A 2014-11-12 2015-11-12 グリカン相互作用化合物及び使用方法 Expired - Fee Related JP6951973B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021066180A JP2021118699A (ja) 2014-11-12 2021-04-09 グリカン相互作用化合物及び使用方法
JP2023034165A JP2023063357A (ja) 2014-11-12 2023-03-07 グリカン相互作用化合物及び使用方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201462078610P 2014-11-12 2014-11-12
US62/078,610 2014-11-12
US201562102527P 2015-01-12 2015-01-12
US62/102,527 2015-01-12
US201562145214P 2015-04-09 2015-04-09
US62/145,214 2015-04-09
US201562173560P 2015-06-10 2015-06-10
US62/173,560 2015-06-10
US201562187587P 2015-07-01 2015-07-01
US62/187,587 2015-07-01
PCT/US2015/060287 WO2016077526A1 (en) 2014-11-12 2015-11-12 Glycan-interacting compounds and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021066180A Division JP2021118699A (ja) 2014-11-12 2021-04-09 グリカン相互作用化合物及び使用方法

Publications (3)

Publication Number Publication Date
JP2018503600A JP2018503600A (ja) 2018-02-08
JP2018503600A5 true JP2018503600A5 (enExample) 2020-07-02
JP6951973B2 JP6951973B2 (ja) 2021-10-20

Family

ID=55955018

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017526592A Expired - Fee Related JP6951973B2 (ja) 2014-11-12 2015-11-12 グリカン相互作用化合物及び使用方法
JP2021066180A Pending JP2021118699A (ja) 2014-11-12 2021-04-09 グリカン相互作用化合物及び使用方法
JP2023034165A Pending JP2023063357A (ja) 2014-11-12 2023-03-07 グリカン相互作用化合物及び使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021066180A Pending JP2021118699A (ja) 2014-11-12 2021-04-09 グリカン相互作用化合物及び使用方法
JP2023034165A Pending JP2023063357A (ja) 2014-11-12 2023-03-07 グリカン相互作用化合物及び使用方法

Country Status (15)

Country Link
US (5) US20170306046A1 (enExample)
EP (2) EP3218005B1 (enExample)
JP (3) JP6951973B2 (enExample)
CA (1) CA2967595A1 (enExample)
CY (1) CY1125977T1 (enExample)
DK (1) DK3218005T5 (enExample)
ES (1) ES2941897T3 (enExample)
FI (1) FI3218005T3 (enExample)
HU (1) HUE061672T2 (enExample)
IL (3) IL278574B2 (enExample)
MX (2) MX2017006167A (enExample)
PL (1) PL3218005T3 (enExample)
PT (1) PT3218005T (enExample)
SI (1) SI3218005T1 (enExample)
WO (1) WO2016077526A1 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
CN105939767B (zh) 2014-01-08 2018-04-06 弗洛设计声能学公司 具有双声电泳腔的声电泳装置
MX2017006167A (es) * 2014-11-12 2018-03-23 Siamab Therapeutics Inc Compuestos que interactúan con glicanos y métodos de uso.
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
RU2754661C2 (ru) 2015-05-01 2021-09-06 Дзе Реджентс Оф Дзе Юниверсити Оф Калифорния Гликанзависимые иммунотерапевтические молекулы
WO2016201240A1 (en) * 2015-06-12 2016-12-15 Siamab Therapeutics, Inc. Compositions and methods for targeting cancer stem cells
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
TWI660741B (zh) 2015-11-03 2019-06-01 財團法人工業技術研究院 抗體藥物複合物及其製造方法
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
EP3529347A1 (en) 2016-10-19 2019-08-28 Flodesign Sonics, Inc. Affinity cell extraction by acoustics
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CA3048312A1 (en) * 2017-01-01 2018-07-05 Chi-Yu Gregory Lee Rp215 chimeric antigen receptor construct and methods of making and using same
CA3052446A1 (en) * 2017-02-02 2018-08-09 The Scripps Research Institute Engineered cells and methods of use
AU2018219226B2 (en) 2017-02-07 2024-12-19 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
KR20240044544A (ko) * 2017-03-03 2024-04-04 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
CN114900773A (zh) 2017-12-14 2022-08-12 弗洛设计声能学公司 声泳系统及其操作方法、控制声换能器及声学系统的方法
WO2019144095A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
AU2019218729B2 (en) 2018-02-06 2025-12-04 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors
JP7568224B2 (ja) 2018-02-23 2024-10-16 エンドサイト・インコーポレイテッド Car t細胞療法のための配列決定法
AU2019267349B2 (en) * 2018-05-08 2025-06-05 Phanes Therapeutics, Inc. Anti-DLL3 antibodies and uses thereof
MX2021012336A (es) * 2019-04-08 2021-11-12 Phanes Therapeutics Inc Receptores de antigeno quimerico anti-dll3 humanizados y usos de los mismos.
WO2021105989A1 (en) * 2019-11-26 2021-06-03 Ramot At Tel-Aviv University Ltd. Chimeric antigen receptor to carbohydrate antigens
WO2021105988A1 (en) 2019-11-26 2021-06-03 Ramot At Tel-Aviv University Ltd. Antibodies to carbohydrate antigens
IL295063A (en) 2020-02-04 2022-09-01 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Chimeric antigen receptors (car) against dinitrophenol
EP4251653A4 (en) * 2020-11-24 2024-06-19 Ramot at Tel-Aviv University Ltd. HUMANIZED ANTIBODIES AND FRAGMENTS THEREOF THAT BIND TO CARBOHYDRATE ANTIGENS AND USES THEREOF
KR20250152662A (ko) 2020-12-31 2025-10-23 사노피 NKp46 및 CD123에 결합하는 다기능성 자연살해(NK) 세포 관여자
US12406510B2 (en) * 2021-03-26 2025-09-02 Howard University Method for the detection, segmentation and morphological mapping on neural cell images of the whole brain
US20240216510A1 (en) * 2021-04-20 2024-07-04 Ramot At Tel-Aviv University Ltd. Chimeric antigen receptors to sialyl-tn glycan antigen
WO2022224242A1 (en) * 2021-04-20 2022-10-27 Ramot At Tel-Aviv University Ltd. Humanized anti-sialyl-tn glycan antibodies and uses thereof
US20240190951A1 (en) * 2021-04-23 2024-06-13 Amgen Inc. Anti-tslp antibody compositions and uses thereof
WO2023154708A2 (en) * 2022-02-10 2023-08-17 The Scripps Research Institute Car-t therapies targeted via covalently bonded adapters
WO2023192798A2 (en) * 2022-03-28 2023-10-05 Coherus Biosciences, Inc. Anti-ilt4 compositions and methods
WO2023227790A1 (en) 2022-05-27 2023-11-30 Sanofi Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
GB2619976A (en) * 2022-06-24 2023-12-27 Cellmabs S A Humanised antibodies or functional fragments thereof against tumour antigens
CN116102652B (zh) * 2022-10-11 2024-05-31 上海交通大学医学院附属瑞金医院 一种抗rcp抗体及其制备方法
WO2024193989A1 (en) 2023-03-17 2024-09-26 Danmarks Tekniske Universitet Combotope antibody libraries
WO2024193794A1 (en) * 2023-03-17 2024-09-26 Danmarks Tekniske Universitet Combotope antibody libraries
WO2025006452A2 (en) * 2023-06-26 2025-01-02 Sri International NEU5GC-LEWISa-TARGETING MOLECULES AND USES THEREOF IN CANCER
WO2026032010A1 (en) * 2024-08-05 2026-02-12 The Hong Kong University Of Science And Technology Glycan-targeting protein aggregation therapy

Family Cites Families (246)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807A (en) 1848-09-26 Brake fob cabs
US715A (en) 1838-04-28 Improvement in water-wheels
US823244A (en) 1906-01-18 1906-06-12 Emerson Mfg Co Wheeled plow.
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US6872868B1 (en) 1981-06-12 2005-03-29 Ohio University Transgenic mammals
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IN164232B (enExample) 1986-04-11 1989-02-04 Hoechst India
US4695198A (en) 1986-05-23 1987-09-22 Chevron Research Company Lip-type sealing system for a removable bottom founded structure
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
EP0256654B1 (en) * 1986-07-07 1996-09-18 Centocor, Inc. Chimeric murine/human immunoglobulin specific for tumour-associated 17-1A Antigen
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5059680A (en) 1986-11-24 1991-10-22 Centocor, Inc. Method of isolating ca 125 antigen
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
CA1340927C (en) 1987-10-09 2000-03-14 Peter S. Linsley Method for increasing the sensitivity of assays for target ligand
IT1212041B (it) 1987-11-02 1989-11-08 Fidia Farmaceutici Gangliosidi esteri interni come agenti terapeutici capaci di eliminare il dolore nelle neuropatie periferiche
JPH02486A (ja) 1987-11-13 1990-01-05 Mect Corp 遊離n−アセチルノイラミン酸を認識するモノクローナル抗体
US4978745A (en) 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9012995D0 (en) * 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DK0553244T4 (da) 1990-10-05 2005-08-01 Celldex Therapeutics Inc Målrettet immunostimulering med bispecifikke reagenser
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
EP0582595A1 (en) 1991-04-26 1994-02-16 Surface Active Limited Novel antibodies, and methods for their use
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0563475B1 (en) 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5951983A (en) 1993-03-05 1999-09-14 Universite Catholique De Louvain Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
US20030108548A1 (en) 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
ES2201097T3 (es) 1994-01-31 2004-03-16 Trustees Of Boston University Bibliotecas de anticuerpos policlonales.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US5919652A (en) 1994-11-09 1999-07-06 The Regents Of The University Of California Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof
US5710038A (en) 1994-11-25 1998-01-20 Universite De Montreal Primary cultures of normal and tumoral human ovarian epithelium
US5811510A (en) 1995-04-14 1998-09-22 General Hospital Corporation Biodegradable polyacetal polymers and methods for their formation and use
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US5849733A (en) 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
AU720802B2 (en) 1996-07-03 2000-06-15 Millenium Pharmaceuticals, Inc. Detection of cancer by assaying for cancer-specific antigens having linked oligosaccharides which are at least triantennary
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド 人工抗体ポリペプチド
JP2001516766A (ja) 1997-09-19 2001-10-02 デイナ−ファーバー キャンサー インスティチュート,インコーポレイテッド 免疫反応の細胞内発現抗体仲介制御
US6852533B1 (en) 1998-01-23 2005-02-08 Cornell Research Foundation, Inc. Purified populations of stem cells
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US20030170249A1 (en) 1999-02-19 2003-09-11 Hakomori Sen-Itiroh Vaccines directed to cancer-associated carbohydrate antigens
US20020012660A1 (en) 1999-03-04 2002-01-31 Alan Colman Method of preparing a somatic cells for nuclear transfer
GB2344886B (en) 1999-03-10 2000-11-01 Medical Res Council Selection of intracellular immunoglobulins
AU5744800A (en) 1999-06-16 2001-01-02 Biocrystal Limited Vaccine formulations and methods for immunizing an individual against shed antigen-specific b cells
ATE456578T1 (de) 1999-12-06 2010-02-15 Agensys Inc Serpentinetransmembranrezeptoren exprimiert in menschlichem prostatakrebs und ihre verwendungen
WO2001043778A1 (en) 1999-12-17 2001-06-21 Gene Therapy Systems, Inc. Use of cationic lipids for intracellular protein delivery
US20030008813A1 (en) 1999-12-17 2003-01-09 Felgner Philip L. Intracellular protein delivery compositions and methods of use
AU2001253140A1 (en) 2000-04-03 2001-10-15 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Tumor markers in ovarian cancer
IT1317922B1 (it) 2000-10-24 2003-07-15 S I S S A Scuola Internaz Supe Metodo per identificare in vivo epitopi intracellulari.
US7446179B2 (en) 2000-11-07 2008-11-04 City Of Hope CD19-specific chimeric T cell receptor
US20030104402A1 (en) 2001-01-23 2003-06-05 University Of Rochester Methods of producing or identifying intrabodies in eukaryotic cells
US20040047891A1 (en) 2001-02-26 2004-03-11 Sabina Glozman Systems devices and methods for intrabody targeted delivery and reloading of therapeutic agents
GB0108165D0 (en) 2001-03-31 2001-05-23 Univ Manchester Intracellular analysis
US20030171546A1 (en) 2001-04-30 2003-09-11 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7514537B2 (en) 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
AU2002308533B2 (en) 2001-04-30 2007-07-19 Rbc Biotechnology, Inc Modified organs and cells for xenotransplantation
KR100486784B1 (ko) 2001-05-22 2005-04-29 김하형 솔비나무로 부터 추출된 렉틴 단백질, 그의 제조방법 및용도
US20020192231A1 (en) 2001-05-24 2002-12-19 Immucom Inc. Method of increasing anti-neuGc antibody levels in blood
US6814734B2 (en) 2001-06-18 2004-11-09 Sdgi Holdings, Inc, Surgical instrumentation and method for forming a passage in bone having an enlarged cross-sectional portion
JP4355571B2 (ja) 2001-07-19 2009-11-04 ウニベルジテート チューリッヒ ヒト可変ドメインの改変
CA2456121A1 (en) 2001-08-03 2003-02-20 Medical Research Council Intracellular antibodies
EP1419176A2 (en) 2001-08-17 2004-05-19 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Glycoconjugates of sialic acid derivates, methods for their production and use thereof
WO2003040185A2 (de) 2001-11-09 2003-05-15 Hexal Biotech Forschungsgmbh Anti-n-glykolyl-neuraminsäure-antikörper und ihre verwendung zur bestimmung von glykoproteinen
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
NZ534069A (en) 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
GB0201611D0 (en) 2002-01-24 2002-03-13 Grosveld Frank Transgenic animal
GB0226723D0 (en) 2002-11-15 2002-12-24 Medical Res Council Antibodies for in vitro use
GB0226727D0 (en) 2002-11-15 2002-12-24 Medical Res Council Intrabodies
AU2003219277A1 (en) 2002-03-14 2003-09-29 Medical Research Council Intracellular antibodies
AU2003222171A1 (en) 2002-04-05 2003-10-27 Selective Genetics, Inc. Compositions and methods for portal specific gene delivery and treatment of infection
CN102093477B (zh) 2002-05-22 2014-02-26 艾斯巴技术-诺华有限责任公司 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
GB0226731D0 (en) 2002-11-15 2002-12-24 Medical Res Council Method for generating immunoglobulin genes
EP1565495A2 (en) 2002-11-15 2005-08-24 Medical Research Council Anti-activated ras antibodies
GB0226729D0 (en) 2002-11-15 2002-12-24 Medical Res Council Intracellular antibodies
ITRM20020588A1 (it) 2002-11-21 2004-05-22 Lay Line Genomics Spa Metodo per isolare anticorpi intracellulari neutralizzanti di interazioni proteiche.
EP1482309A1 (en) 2003-05-07 2004-12-01 Institut Curie Means for detecting protein conformation and applications thereof
DE602004017474D1 (de) 2003-07-11 2008-12-11 Warner Lambert Co Isethionat salz eines selektiven cdk4 inhibitors
US7682794B2 (en) 2003-07-15 2010-03-23 The Regents Of The University Of California Methods for detecting and analyzing N-glycolylneuraminic acid (Neu5Gc) in biological materials
ITMI20031909A1 (it) 2003-10-03 2005-04-04 Keryos Spa Linee cellulari di mammifero modificate per la produzione di glicoproteine ricombinanti.
AU2004309373A1 (en) 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
WO2005088310A2 (en) 2004-03-05 2005-09-22 The Scripps Research Institute High throughput glycan microarrays
EP1740616B1 (en) 2004-04-30 2011-12-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-tfr antibody.
KR100620554B1 (ko) 2004-06-05 2006-09-06 한국생명공학연구원 Tag-72에 대한 인간화 항체
JP2008504531A (ja) 2004-06-24 2008-02-14 ザ スクリップス リサーチ インスティテュート 切断可能なリンカーを有するアレイ
US7638467B2 (en) 2004-08-03 2009-12-29 Intevep, S.A. Reversible gelling system and method using same during well treatments
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
WO2006068758A2 (en) 2004-11-19 2006-06-29 The Scripps Research Institute Detection, prevention and treatment of breast cancer
US7811572B2 (en) 2005-08-24 2010-10-12 Immunogen, Inc. Process for preparing purified drug conjugates
CA2606102C (en) 2005-04-26 2014-09-30 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
AU2006254862B2 (en) 2005-06-08 2011-04-07 The Regents Of The University Of California Elimination of N-glycolylneuraminic acid from mammalian products for human use
SI1964852T1 (sl) 2005-12-20 2013-09-30 Sbi Biotech Co. Ltd. Proti-ilt7 protitelo
WO2007079448A2 (en) 2006-01-03 2007-07-12 University Of Georgia Research Foundation, Inc. Three component carbohydrate vaccine
WO2010002478A2 (en) 2008-07-03 2010-01-07 University Of Georgia Research Foundation, Inc. Glycopeptide and uses thereof
ATE509027T1 (de) 2006-01-13 2011-05-15 Pasteur Institut Enzymatische synthese von grossen mengen von mucin glyconjugaten und deren immunogenische anwendungen
EP2004221A2 (en) 2006-03-23 2008-12-24 Novartis Pharma AG Anti-tumor cell antigen antibody therapeutics
WO2007116779A1 (ja) 2006-03-31 2007-10-18 Mochida Pharmaceutical Co., Ltd. 新規血小板活性化マーカー及びその測定方法
US20070265170A1 (en) 2006-05-15 2007-11-15 Ola Blixt Detection, prevention and treatment of ovarian cancer
GB0613209D0 (en) 2006-07-03 2006-08-09 Ucb Sa Methods
JP2010505775A (ja) 2006-10-04 2010-02-25 クーベンハヴンス・ユニヴェルシテット Muc1に対する癌特異的な免疫反応の産生及び癌特異的muc1抗体
EP2077863A4 (en) 2006-10-31 2010-10-06 Domantis Ltd intrabodies
EP2082234B1 (en) 2006-11-02 2012-10-03 Procognia (Israel) Ltd. Methods for screening for therapeutic molecules and use of the molecules therefrom
WO2009018438A1 (en) 2007-07-31 2009-02-05 Cornell Research Foundation, Inc. Protein discovery using intracellular ribosome display
EP2014302A1 (en) 2007-07-12 2009-01-14 Institut Curie An antibody specific for the Tn antigen for the treatment of cancer
WO2009035494A2 (en) 2007-07-30 2009-03-19 The Scripps Research Institute Methods for producing anti-glycan antibodies, vaccines and methods for treating cancer or infectious disease
FI20070853A0 (fi) 2007-11-09 2007-11-09 Glykos Finland Oy Glykaania sitovat monoklonaaliset vasta-aineet
MX2010005282A (es) 2007-11-13 2010-08-31 Teva Pharma Anticuerpos humanizados contra tl1a.
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
US8506966B2 (en) 2008-02-22 2013-08-13 Novartis Ag Adjuvanted influenza vaccines for pediatric use
US20120027813A1 (en) 2008-02-22 2012-02-02 Novartis Vaccines And Diagnostics Srl Adjuvanted influenza vaccines for pediatric use
US8298773B2 (en) 2008-05-02 2012-10-30 Marko Vuskovic Methods, assays and kits for cancer diagnosis and screening utilizing glycan-binding and glycan epitopes
WO2009147695A1 (ja) 2008-06-02 2009-12-10 国立大学法人東京大学 抗がん剤
EP2143735A1 (en) 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
US20100009424A1 (en) 2008-07-14 2010-01-14 Natasha Forde Sonoporation systems and methods
FI20095418A0 (fi) 2009-04-16 2009-04-16 Suomen Punainen Risti Veripalv Kryptinen subpopulaatio
AU2009284098B2 (en) 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
US20120045816A1 (en) 2008-09-09 2012-02-23 Sialix, Inc. Novel Glycosylated Polypeptides
EP2324110A4 (en) 2008-09-09 2013-01-09 Univ California ELIMINATION OF A CONTAMINATING NON-HUMAN SIALIC ACID BY METABOLISM COMPETITION
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
US20100178292A1 (en) 2009-01-12 2010-07-15 The Board Of Trustees Of The Leland Stanford Junior University Cryptic glycan markers and applications thereof
US8669085B2 (en) 2009-02-05 2014-03-11 Ut-Battelle, Llc Transformation of gram positive bacteria by sonoporation
JP2012528240A (ja) 2009-05-28 2012-11-12 メルサナ セラピューティックス, インコーポレイテッド 可変速度放出リンカーを含むポリアル−薬物コンジュゲート
US8399625B1 (en) 2009-06-25 2013-03-19 ESBATech, an Alcon Biomedical Research Unit, LLC Acceptor framework for CDR grafting
CA2766409C (en) 2009-07-03 2023-04-25 Avipep Pty Ltd Immuno-conjugates and methods for producing them
EP2275442A1 (en) 2009-07-06 2011-01-19 Ludwig-Maximilians-Universität München Detection and vizualization of the cell cycle in living cells
WO2011016238A1 (en) 2009-08-06 2011-02-10 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
EP2287202A1 (en) * 2009-08-07 2011-02-23 Dublin City University Anti-sialic acid antibody molecules
JP5934099B2 (ja) 2009-10-01 2016-06-15 アメリカ合衆国 抗血管内皮増殖因子受容体−2キメラ抗原受容体及び癌の治療のためのその使用
CA2781682A1 (en) 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
WO2011088385A2 (en) 2010-01-15 2011-07-21 The Regents Of The University Of California Compositions and methods for detecting cancer
EP2347769A1 (en) 2010-01-20 2011-07-27 Glycotope GmbH Cancer stem cell markers and uses thereof
WO2011135869A1 (ja) 2010-04-28 2011-11-03 塩野義製薬株式会社 新規なmuc1抗体
US20120114652A1 (en) 2010-05-03 2012-05-10 Abbott Laboratories Anti-pai-1 antibodies and methods of use thereof
WO2011156751A2 (en) 2010-06-11 2011-12-15 University Of Georgia Research Foundation, Inc. Immunogenic vaccine
KR20140003380A (ko) 2010-07-13 2014-01-09 울트라제닉스 파마수티컬 인코포레이티드 시알산 결함 치료용 방법들 및 제형들
EP2407487A1 (en) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
CA2814040C (en) 2010-10-08 2021-03-23 Joshua Michael Donaldson A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
AR083797A1 (es) 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
MX2013006234A (es) 2011-01-06 2013-08-01 Univ Johns Hopkins Metodo para la produccion de glicoproteinas recombinantes con semivida en circulacion incrementada en celulas de mamifero.
WO2012106465A2 (en) 2011-02-01 2012-08-09 Hibm Research Group, Inc. Methods and compositions for increasing sialic acid production and treating sialic related disease conditions
US20140005069A1 (en) 2011-03-01 2014-01-02 Glycosensors And Diagnostics, Llc. Glycoprofiling with multiplexed suspension arrays
US9487583B2 (en) 2011-03-30 2016-11-08 National University Corporation University Of Toyama Method for selecting plasma cells or plasmablasts, method for producing target antigen specific antibodies, and novel monoclonal antibodies
EP2717916B1 (en) 2011-06-10 2017-03-08 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
WO2013023251A1 (en) 2011-08-18 2013-02-21 Affinity Biosciences Pty Ltd Soluble polypeptides
WO2013033420A1 (en) 2011-08-30 2013-03-07 Whitehead Institute For Biomedical Research Methods of downregulating translocated oncogene expression using bromodomain inhibitors
KR20140060541A (ko) 2011-09-16 2014-05-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암을 치료하기 위한 rna 조작된 t 세포
KR102276792B1 (ko) 2011-10-10 2021-07-15 시티 오브 호프 메디토프와 메디토프-결합 항체 및 이들의 용도
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
CN104203981A (zh) 2011-12-19 2014-12-10 合成免疫股份有限公司 双特异性抗体分子
TW201333040A (zh) 2012-01-06 2013-08-16 Bioalliance Cv 抗-輸鐵蛋白受器之抗體及其使用方法
CA3285826A1 (en) 2012-02-22 2026-03-02 The Trustees Of The University Of Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
EP2825561A4 (en) 2012-03-15 2016-03-09 Permeon Biolog Inc CELL PENETRATING COMPOSITIONS FOR THE DISPOSAL OF INTRA-CELLULAR ANTIBODIES AND ANTIBODY-RELATED UNITS AND METHODS OF USE
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
EP2850106B1 (en) 2012-05-18 2022-03-23 Aptevo Research and Development LLC Bispecific scfv immunofusion (bif) binding to cd123 and cd3
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
CN113234142B (zh) 2012-08-22 2024-03-05 财团法人牧岩生命工学研究所 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用
WO2014039513A2 (en) 2012-09-04 2014-03-13 The Trustees Of The University Of Pennsylvania Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
US9598489B2 (en) 2012-10-05 2017-03-21 The Trustees Of The Univeristy Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
US20150284455A1 (en) 2012-11-06 2015-10-08 Scholar Rock, Inc. Compositions and methods for modulating cell signaling
US10226535B2 (en) 2012-12-10 2019-03-12 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
DK2935331T3 (en) 2012-12-24 2018-06-06 Abbvie Inc PROLACTIN RECEPTOR BINDING PROTEINS AND APPLICATIONS THEREOF
EP2752487A1 (en) 2013-01-03 2014-07-09 Sanofi Intracellular phenotypic screening
WO2014160360A1 (en) 2013-03-14 2014-10-02 Mersana Therapeutics Inc. Tubulysin compounds and conjugates thereof
CN105530959B (zh) 2013-03-15 2021-09-17 纪念斯隆-凯特琳癌症中心 多聚化技术
EP2970485A1 (en) 2013-03-15 2016-01-20 Merck Patent GmbH Tetravalent bispecific antibodies
WO2015013429A1 (en) 2013-07-23 2015-01-29 The Ohio State University Methods and compositions related to single chain antibody fragments that bind to tumor-associated glycoprotein 72 (tag-72)
WO2015048748A1 (en) 2013-09-30 2015-04-02 Board Of Regents, The University Of Texas System Myeloid-derived suppressor cell-specific peptides for diagnostic and therapeutic use
EP3054974A4 (en) 2013-10-10 2017-06-14 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
SG10201807208RA (en) 2014-03-04 2018-09-27 Sigma Aldrich Co Llc Viral resistant cells and uses thereof
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
LT3148579T (lt) 2014-05-28 2021-05-25 Agenus Inc. Anti-gitr antikūnai ir jų panaudojimo būdai
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗her2表位之單株抗體及其使用之方法
CN106714822A (zh) 2014-08-27 2017-05-24 昂科梅德制药有限公司 用于治疗癌症的组合治疗
US20180280504A1 (en) 2014-10-10 2018-10-04 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US20170305950A1 (en) 2014-10-10 2017-10-26 Siamab Therapeutics, Inc. Glycan analysis and profiling
MX2017006167A (es) 2014-11-12 2018-03-23 Siamab Therapeutics Inc Compuestos que interactúan con glicanos y métodos de uso.
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
KR102618312B1 (ko) 2015-03-17 2023-12-28 메모리얼 슬로안 케터링 캔서 센터 항muc16 항체 및 그의 용도
EP3091032A1 (en) 2015-05-08 2016-11-09 Miltenyi Biotec GmbH Humanized antibody or fragment thereof specific for cd3
WO2016201240A1 (en) 2015-06-12 2016-12-15 Siamab Therapeutics, Inc. Compositions and methods for targeting cancer stem cells
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US20190031780A1 (en) 2016-01-27 2019-01-31 Siamab Therapeutics, Inc. Compositions and methods for targeting cancer stem cells
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US20200247902A1 (en) 2016-11-17 2020-08-06 Seattle Genetics, Inc. Compositions and methods for treating cancer
KR20240044544A (ko) 2017-03-03 2024-04-04 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법

Similar Documents

Publication Publication Date Title
CN108124445B (zh) Ctla4抗体、其药物组合物及其用途
JP2022163013A (ja) グリコシル化免疫チェックポイントタンパク質に特異的に結合する抗体を選択する方法
JP2020182492A (ja) 抗cd137抗体
CN114206931B (zh) 抗pd-1抗体及其用途
JP2016523265A (ja) 抗pd−1抗体およびその応用
AU2014361473A1 (en) PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
CN117120469A (zh) 抗tnfr2人源化抗体及其用途
WO2010132532A1 (en) B cell surface reactive antibodies
TW201942130A (zh) 結合至ssea4的單株抗體及其用途
CN108623685A (zh) 抗ox40抗体及其用途
JP7009642B2 (ja) 抗-vista抗体及びその用途
CN106999576A (zh) 癌细胞特异性抗体、抗癌剂、及癌症的检查方法
CN113788894A (zh) 靶向人Claudin18.2蛋白的单克隆抗体及其应用
EP3565598A1 (en) Native human antibodies for immune checkpoint modulation targets tim-3 and b7-h3
TW201927819A (zh) 雙專一性抗體及製造與使用其的方法
WO2024141027A1 (zh) 一种双特异性抗体及其应用
KR20210027254A (ko) Tim-3에 대한 항체 및 그의 용도
TW202340240A (zh) 多特異性抗體及其藥物用途
CN120659810A (zh) 抗cdh6的抗体及其用途
CN120344653A (zh) 成纤维细胞活化蛋白(fap)car-恒定型自然杀伤t细胞及其用途
CN105985435B (zh) 全人源her2抗体的突变抗体及其编码基因和应用
US20250090663A1 (en) Binding domains and methods of use thereof
CN115433277A (zh) 抗cd38兔重组单克隆抗体的制备及应用
CN118317788B (zh) Tnfr2结合分子及其用途
CN113087796B (zh) 一种抗pd-l1抗体及其应用